Investors & Media : on Data Provided by Refinitiv. Minimum 15 minutes delayed. Intra 3 mo. 6 mo. 1 yr. News Releases Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint Sep 30, 2022 Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning Sep 21, 2022 Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology Sep 20, 2022 Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences Sep 07, 2022 View all press releases > Recent Events and Presentations Baird Global Healthcare Conference Sep 14, 2022 at 9:05 AM EDT H.C. Wainwright 24th Annual Global Investment Conference Sep 13, 2022 at 5:00 PM EDT Primary Biliary Cholangitis (PBC) Mini Symposium: Orphan Liver Disease That May Not Be As Rare As You’d Think Aug 24, 2022 at 1:00 PM EDT Q2 2022 Intercept Pharmaceuticals Earnings Call Aug 3, 2022 at 8:30 AM EDT View all events & presentations >
Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint Sep 30, 2022
Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning Sep 21, 2022
Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology Sep 20, 2022
Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences Sep 07, 2022
Primary Biliary Cholangitis (PBC) Mini Symposium: Orphan Liver Disease That May Not Be As Rare As You’d Think Aug 24, 2022 at 1:00 PM EDT
